撰文丨王聪 编辑丨王多鱼 排版丨水成文 血管性痴呆 （VaD） 约占所有痴呆病例的 25%，是仅次于 阿尔茨海默病 （AD） 的第二常见痴呆类型。值得注意的是，血管性痴呆 （VaD） 常与阿尔茨海默 病 （AD） 共存，84% 的老年人同时表现出血管性痴呆的形态特征和阿尔茨海默病的病理变化，表明这两种疾病可能存在累加或协同作用。 尽管血管性痴呆 （VaD） 的发病率很高，且对全球健康有着深远影响，但其潜在发病机制仍知之甚少。目前，尚无针对血管性痴呆 （VaD） 的直接治疗方法， 现有的对症疗法 （例如胆碱酯酶抑制剂和美金刚） 疗效有限，且未能针对潜在的血管病变。这些知识空白凸显了开展全面研究的紧迫性，以确定治疗靶点，并在 能准确模拟人类血管性痴呆 （VaD） 多样病因的动物模型中验证其可转化性。 2025 年 6 月 30 日 ， 加州大学洛杉矶分校 S. Thomas Carmichael 团队 （博士后 田敏 为第一作者） 在国际顶尖学术期刊 Cell 上发表了题为 ： Deconstructing the intercellular interactome in vascular dementia wi ...

Ramat Gan, Israel, June 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that Dr. Sari Fishman, Vice President of Business Development, will present an update on the Company’s ongoing Phase IIa study in pancreatic cancer during partnering meetings at the 2025 BIO International Convention, taking place J ...

Industry Overview - The psoriasis market is projected to reach $30 billion by 2030, with a significant shift towards oral drugs [1] Company Developments - Can-Fite BioPharma Ltd. has initiated a pivotal Phase 3 study for its oral drug Piclidenoson, targeting moderate to severe plaque psoriasis, with patient enrollment starting in Europe and expected to follow in the US and Canada [1][3] - The Phase 3 study is randomized, double-blind, and placebo-controlled, focusing on the safety and efficacy of Piclidenoson, with co-primary efficacy objectives including achieving a PASI score response of ≥75% and a sPGA score of 0 or 1 at Week 16 [2] - The FDA has requested two Phase 3 studies and encouraged the enrollment of adolescent patients due to the drug's strong safety profile [2] - Upon successful completion of the Phase 3 program, the company plans to submit a New Drug Application (NDA) to the FDA and a Marketing Authorization Plan (MAA) to the EMA [3] Product Information - Piclidenoson is a first-in-class A3 adenosine receptor agonist, demonstrating an excellent safety profile and efficacy in previous clinical studies, targeting inflammatory cytokines IL-17 and IL-23 [4] - Can-Fite's lead drug candidate, Piclidenoson, is part of a broader pipeline that includes other drugs like Namodenoson, which is being evaluated for various cancers and has received Orphan Drug Designation and Fast Track Designation from the FDA [5]